REC Ref No.	IRAS No.	Name of Trial	Target Number of Participants Available?	Recruitment Target	Target Date To Recruit Participants Available?	Date Agreed To Recruit Target Number of Participants	Total Number of Participants Recruited at The Agreed Target Date	Date Study Closed to Recruitment	Recruitment Total	RTT Met?	Recruitment Closure Reason
20/HRA/2068	283394	A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome	Number Agreed	5	Date Agreed	29/06/2020	0	29/06/2020	0	No	Recruitment Finished
20/WM/0123	282099	A randomized, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia	Range Agreed	3	Date Agreed	29/01/2021	12	28/05/2020	12	Yes	Recruitment Finished
20/NE/0105	282026	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment	Number Agreed	4	Date Agreed	04/06/2020	3	29/05/2020	3	Yes	Recruitment Finished
20/NE/0104	282007	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants with Severe COVID-19	Number Agreed	6	Date Agreed	29/05/2020	6	29/05/2020	6	Yes	Recruitment Finished
20/YH/0090	278137	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMERâ€™S DISEASE	Number Agreed	2	Date Agreed	07/09/2020	2	30/09/2020	2	Yes	Recruitment Finished
18/NS/0145	254786	A NON-INTERVENTIONAL, MULTICENTER, MULTIPLE COHORT STUDY INVESTIGATING THE OUTCOMES AND SAFETY OF ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE	Number Agreed	2	Date Agreed	31/12/2020	2	31/12/2020	2	Yes	Recruitment Finished
19/LO/1566	267041	A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease	Number Agreed	1	Date Agreed	30/09/2020	0	06/04/2020	0	No	Recruitment Finished
18/WS/0187	242800	Retrospective and prospective international EKoSoNicÂ® registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism	Number Agreed	3	Date Agreed	31/03/2020	2	30/09/2020	2	No	Recruitment Finished
19/EE/0164	261589	T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.	Number Agreed	3	Date Agreed	07/09/2020	0	12/05/2020	0	No	Withdrawn By Sponsor
19/LO/1263	263485	A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk	Number Agreed	3	Date Agreed	01/12/2020	1	01/12/2020	1	No	Recruitment Finished
19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	Date Agreed	31/12/2020	0	15/03/2021	0	No	Recruitment Finished

18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	2	Date Agreed	30/06/2020	1	30/06/2020	3	Yes	Recruitment Finished
19/NW/0174	261666	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers	Number Agreed	3	Date Agreed	31/12/2020	6	30/10/2020	6	Yes	Recruitment Finished
19/EM/0020	252705	A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER)	Number Agreed	2	Date Agreed	30/11/2020	3	30/11/2020	3	Yes	Recruitment Finished
19/LO/0150	258058	A double-blind, placebo-controlled, randomised phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age	Number Agreed	10	Date Agreed	30/07/2020	7	30/07/2020	7	No	Recruitment Finished
19/NW/0342	264974	A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)	Range Agreed	2	Date Agreed	20/12/2020	0	20/12/2020	0	No	Recruitment Finished
18/EE/0099	239606	An open label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)	Number Agreed	10	Date Agreed	31/03/2020	2	19/08/2020	2	No	Recruitment Finished
19/YH/0013	255993	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who have not received Previous Systemic Anticancer therapy.	Number Agreed	3	Date Agreed	01/04/2023	3	19/08/2020	3	Yes	Recruitment Finished
19/LO/1183	259840	IPX203-B16-02	Number Agreed	3	Date Agreed	30/07/2020	1	30/07/2020	3	Yes	Recruitment Finished
19/SC/0350	266934	A Phase 1B, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Inhaled GB002, and Assess Changes in Imaging and Biomarkers in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)	Number Agreed	2	Date Agreed	31/10/2020	1	31/12/2020	1	No	Recruitment Finished
18/EM/0256	248467	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction	Number Agreed	3	Date Agreed	29/06/2020	0	30/11/2020	0	No	Recruitment Finished
17/LO/0232	220795	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinsonâ€™s Disease Complicated by Motor Fluctuations	Number Agreed	4	Date Agreed	30/04/2020	1	17/03/2021	2	No	Recruitment Finished
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	Number Agreed	8	Date Agreed	11/01/2021	9	11/01/2021	9	Yes	Recruitment Finished

18/WA/0276	246112	Randomised Double-Blind, Placebo-Controlled (within dose groups) and Active Controlled (Eplerenone group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients with Diabetic Nephropathy	Number Agreed	2	Date Agreed	30/10/2020	0	29/07/2020	0	No	Recruitment Finished
18/NW/0765	250220	Validating a Device for the Detection of Bacteria and Leukocytes in Peritoneal Effluent from Patients with Suspected Peritonitis	Number Agreed	10	Date Agreed	02/11/2020	13	02/11/2020	13	Yes	Recruitment Finished
16/LO/1567	242092	A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma	Number Agreed	3	Date Agreed	31/08/2020	5	09/04/2020	5	Yes	Recruitment Finished
17/WM/0117	223480	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	Number Agreed	3	Date Agreed	31/01/2021	2	31/01/2021	3	Yes	Recruitment Finished
17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENTâ„¢G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Number Agreed	5	Date Agreed	31/03/2020	5	15/06/2020	4	Yes	Recruitment Finished
18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 â€“ TRial of erYaspase in pancreatic CAncer	Number Agreed	2	Date Agreed	30/08/2020	2	01/12/2020	2	Yes	Recruitment Finished
18/LO/1882	253030	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer	Number Agreed	2	Date Agreed	16/11/2020	2	23/10/2020	2	Yes	Recruitment Finished
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	Number Agreed	3	Date Agreed	01/06/2020	3	01/06/2020	3	Yes	Recruitment Finished
18/NI/0129	218623	Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus LumiganÂ® 0.01% in ocular hypertensive or glaucomatous patients.	Number Agreed	4	Date Agreed	01/05/2020	1	01/05/2020	1	No	Withdrawn By Sponsor
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-ChekÃ‚Â® Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPodÃ‚Â® in Patients with Type 1 Diabetes	Number Agreed	4	Date Agreed	31/05/2020	0	31/05/2020	0	No	Recruitment Finished
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Number Agreed	35	Date Agreed	23/10/2020	34	18/05/2020	34	Yes	Recruitment Finished
18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia	Number Agreed	1	Date Agreed	31/12/2020	3	31/12/2020	3	Yes	Recruitment Finished
18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Number Agreed	2	Date Agreed	31/08/2020	1	02/07/2020	1	No	Withdrawn By Sponsor
18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Number Agreed	1	Date Agreed	01/05/2020	0	01/05/2020	0	No	Recruitment Finished

18/SS/0010	238051	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Number Agreed	1	Date Agreed	27/11/2020	1	27/11/2020	1	Yes	Recruitment Finished
18/WM/0022	237623	AG-348 in Regularly Transfused Adult Subjects with PK Deficiency	Number Agreed	1	Date Agreed	27/09/2020	1	27/09/2020	1	Yes	Recruitment Finished
17/EE/0474	229785	The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients	Number Agreed	5	Date Agreed	21/02/2020	1	09/05/2020	1	No	Recruitment Finished
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, MulticentreStudy of Olaparib Maintenance Retreatment in Patients with EpithelialOvarian Cancer Previously Treated With a PARPi and Responding toRepeat Platinum Chemotherapy (OReO)	Number Agreed	4	Date Agreed	30/04/2021	1	15/01/2021	1	No	Recruitment Finished
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimerâ€™s Disease	Number Agreed	4	Date Agreed	30/06/2020	4	30/06/2020	4	Yes	Recruitment Finished
16/EM/0193	190690	A phase III, double-Â-â€blind, randomized placebo-Â-â€controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-Â-GenE trial	Number Agreed	6	Date Agreed	31/12/2020	6	31/12/2020	6	Yes	Recruitment Finished
04/MRE07/35	31586	Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy	Number Agreed	69	Date Agreed	31/12/2020	76	31/12/2020	76	Yes	Recruitment Finished